Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ADVR: BULLS AND BEARS! -- Ignore unavailable to you. Want to Upgrade?

To: DAN LITTLE who wrote (6093)	5/19/1998 9:54:00 AM
From: DAN LITTLE	Read Replies (1) \| Respond to of 8902

Interesting. Reticulose doesn't have any toxicity problems that I'm aware of. "Problems With Treatment Could Grip World AIDS Meeting" Nando Times Online (05/19/98) Renowned AIDS researcher Robert Gallo, director of the Institute of Human Virology in Baltimore, Md., said Monday that the upcoming 12th World AIDS Conference will focus more on problems with protease inhibitor combination therapy. He noted that the last world meeting on AIDS, two years ago in Vancouver, was overly optimistic, but that the upcoming conference, set for June 28 to July 3 in Geneva, will be more subdued and address the toxicity of the treatment and adherence problems. Gallo did assert, however, that the protease inhibitors were a dramatic step forward in AIDS/HIV treatment, and that the drugs may be working in ways researchers do not yet understand, producing positive immune responses despite the maintenance of HIV viral levels in patients. News of small advances in the hunt for an AIDS vaccine may be reported at the Geneva meeting, but Gallo contends that the vast majority of AIDS research should center on the basic biology of the virus and the development of economical therapies.